1
Ted C K Lee, Michael E Hrinda: Pharmaceutical plasma protein formulations in low ionic strength media. Rorer Pharmaceutical Corporation, Imre J Balogh, James A Nicholson, October 31, 1989: US04877608 (92 worldwide citation)

Stable factor VIII and other plasma protein formulations are provided in low ionic strength media which comprises: sodium chloride, potassium chloride or mixtures thereof; lysine hydrochloride; and histidine as the buffering agent.


2
Ted C K Lee, Michael E Hrinda: Factor VIII formulations in high ionic strength media. Rhone Poulenc Rorer Pharmaceuticals, Raymond S Parker III, Rosanne Goodman, Martin F Savitzky, February 25, 1997: US05605884 (31 worldwide citation)

Stable, highly purified Factor VIII protein formulations are provided in high ionic strength media which comprises: sodium chloride, potassium chloride or mixtures thereof; calcium chloride; and histidine as the buffering agent.


3
Ted C K Lee: Preparation of stable liquid and dried synthetic prothrombin time reagents. International Technidyne Corporation, Duane Morris, May 11, 2004: US06733985 (10 worldwide citation)

A reagent for determining prothrombin time (PT) including a recombinant protein tissue factor, a mixture of synthetic phospholipids, and a beta, gamma, or delta amino acid stabilizing compound is described for monitoring extrinsic blood coagulation activities. The source for the recombinant protein ...


4
David L Farb, Michael E Hrinda, Ted C K Lee, Christopher P Prior, David Weber: Therapeutic fragments of von Willebrand factor. Centeon L L C, Synnestvedt & Lechner, December 8, 1998: US05847086 (7 worldwide citation)

Processes for preparing aqueous solutions of cysteine-altered von Willebrand Factor fragment which are substantially free of aggregate and capable of therapeutic use for treating thrombosis are provided. The claimed process comprises providing an aqueous solution of vWF fragment and denaturant and c ...


5
David L Farb, Michael E Hrinda, Ted C K Lee, Christopher P Prior: Therapeutic fragments of von Willebrand factor. Rh one Poulenc Rorer Pharmaceuticals, Synnestvedt & Lechner, July 23, 1996: US05539086 (6 worldwide citation)

An aqueous solution of cysteine-altered von Willebrand Factor fragment which is substantially free of aggregate and capable of therapeutic use for treating thrombosis and a process for preparing such a solution comprising:


6
Ted C K Lee, Michael E Hrinda: High recovery process for antihemophilic factor. Rorer Pharmaceutical Corporation, Imre, James A Nicholson, December 11, 1990: US04977246 (4 worldwide citation)

Disclosed is a method of recovery of antihemophilic factor (AHF) from human plasma by precipitation with citric acid, sodium citrate, or potassium citrate.


7
Ted C K Lee, Paul Michael D&apos Agostino, Anne Jessica Gorman: Preparation of dried synthetic prothrombin time reagents. International Technidyne Corporation, Arthur L Plevy, Buchanan Ingersoll PC, February 6, 2001: US06183979 (3 worldwide citation)

A method for preparation of an air-dried prothrombin time (PT) reagent which uses a recombinant protein and synthetic phospholipids is described. The source for the recombinant protein is rabbit brain, and the phospholipids employed are palmitoyloleoylphosphatidylcholine (POPC) and palmitoyloleoylph ...


8
Ted C K Lee, Franz H Pelzer, Leslie A Motley: Tetrahydroxyquinone as an activator component for activated partial thromboplastin time test of blood coagulation. Dade International, Lois K Winston, Cynthia G Tymeson, August 27, 1996: US05550028 (1 worldwide citation)

The compound 2,3,5,6-tetrahydroxy-1,4-quinone, its derivatives and structural analogs are used as activators for intrinsic blood coagulation and as diagnostic reagents for the activated partial thromboplastin time test of blood coagulation.


9
Ted C K Lee, Amanda B McBride, Frank M LaDuca: Assay for low molecular weight heparin. International Technidyne Corporation, Synnestvedt & Lechner, April 15, 2008: US07358337

A prothrombin time reagent for determination of low molecular weight heparin in frsh whole blood and in anti-coagulant treated blood is provided. The reagent is composed of recombinant animal tissue factor, and a mixture of synthetic phospholipids, which mixture includes a phosphatidylalcohol. A for ...


10
Ted C K Lee, Amanda B McBride, Frank M LaDuca: Assay for low molecular weight heparin. International Technidyne Corporation, Fox Rothschild, March 15, 2011: US07906299

A prothrombin time reagent for determination of low molecular weight heparin in fresh whole blood and in anti-coagulant treated blood is provided. The reagent is composed of recombinant animal tissue factor, and a mixture of synthetic phospholipids, which mixture includes a phosphatidylalcohol. A fo ...